Hookipa Pharma (NASDAQ:HOOK) Price Target Raised to $24.00 at JMP Securities

Hookipa Pharma (NASDAQ:HOOK) had its price objective increased by research analysts at JMP Securities from $23.00 to $24.00 in a note issued to investors on Friday, Benzinga reports. The brokerage currently has a “market outperform” rating on the stock. JMP Securities’ target price indicates a potential upside of 396.89% from the company’s current price.

A number of other brokerages have also recently weighed in on HOOK. Royal Bank of Canada reiterated an “outperform” rating and set a $50.00 price target on shares of Hookipa Pharma in a research report on Tuesday, May 21st. HC Wainwright lifted their target price on Hookipa Pharma from $50.00 to $60.00 and gave the stock a “buy” rating in a report on Wednesday, June 5th.

Hookipa Pharma Trading Down 4.5 %

HOOK stock traded down $0.23 during midday trading on Friday, hitting $4.83. 19,388 shares of the company’s stock were exchanged, compared to its average volume of 67,667. The firm has a 50 day moving average price of $6.44 and a 200-day moving average price of $7.17. Hookipa Pharma has a 12-month low of $4.10 and a 12-month high of $11.30. The stock has a market capitalization of $47.79 million, a price-to-earnings ratio of -0.97 and a beta of 0.81.

Hookipa Pharma (NASDAQ:HOOK) last posted its quarterly earnings results on Thursday, May 9th. The company reported $1.20 EPS for the quarter, beating the consensus estimate of ($1.20) by $2.40. Hookipa Pharma had a negative net margin of 88.73% and a negative return on equity of 33.33%. The business had revenue of $36.60 million during the quarter, compared to analyst estimates of $3.20 million. During the same period in the previous year, the business posted ($2.70) EPS. On average, sell-side analysts forecast that Hookipa Pharma will post -2.57 EPS for the current fiscal year.

Institutional Investors Weigh In On Hookipa Pharma

An institutional investor recently bought a new position in Hookipa Pharma stock. Virtu Financial LLC bought a new position in Hookipa Pharma Inc (NASDAQ:HOOK) in the 1st quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund bought 43,021 shares of the company’s stock, valued at approximately $31,000. 63.88% of the stock is owned by institutional investors and hedge funds.

Hookipa Pharma Company Profile

HOOKIPA Pharma Inc, a clinical-stage biopharmaceutical company, develops immunotherapeutics targeting infectious diseases and cancers based on its proprietary arenavirus platform. The company's lead infectious disease product candidate is HB-101, which is in a randomized double-blinded Phase 2 clinical trial in cytomegalovirus-negative patients awaiting kidney transplantation from cytomegalovirus-positive donors.